Clinuvel Pharmaceuticals Limited (ASX:CUV)

Clinuvel Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Revenue	86.38	81.22	72.18	60	42.6
Other Revenue	8.63	6.96	6.14	5.72	5.72
Revenue	95.02	88.18	78.32	65.72	48.32
Revenue Growth (YoY)	7.76%	12.58%	19.17%	36.02%	48.37%
Cost of Revenue	8.48	7.73	7.52	9.25	4.17
Gross Profit	86.54	80.45	70.8	56.47	44.15
Selling, General & Admin	30.22	22.84	15.65	13.03	11.57
Research & Development	7.4	2.35	1.27	1.23	0.55
Other Operating Expenses	-0.02	-0.56	-0.02	-0.22	-
Operating Expenses	40.78	31.88	26.67	20.92	15.58
Operating Income	45.76	48.57	44.13	35.55	28.57
Interest Expense	-4.46	-4.45	-3.19	-2.27	-1.62
Interest & Investment Income	9.43	7.32	3.91	0.44	-
Currency Exchange Gain (Loss)	0.83	-0.76	0.74	0.6	-1.37
EBT Excluding Unusual Items	51.55	50.68	45.58	34.32	25.58
Other Unusual Items	-	-	-	-	0.13
Pretax Income	51.55	50.68	45.58	34.32	25.71
Income Tax Expense	15.38	15.04	14.97	13.44	0.98
Earnings From Continuing Operations	36.17	35.64	30.6	20.88	24.73
Net Income	36.17	35.64	30.6	20.88	24.73
Net Income to Common	36.17	35.64	30.6	20.88	24.73
Net Income Growth	1.50%	16.44%	46.58%	-15.57%	64.29%
Shares Outstanding (Basic)	50	50	49	49	49
Shares Outstanding (Diluted)	50	51	52	52	51
Shares Change (YoY)	-1.27%	-1.52%	0.08%	1.26%	1.33%
EPS (Basic)	0.72	0.72	0.62	0.42	0.50
EPS (Diluted)	0.72	0.70	0.59	0.40	0.48
EPS Growth	2.86%	18.11%	46.65%	-16.74%	62.42%
Free Cash Flow	40.8	31.48	35.88	39.44	18.41
Free Cash Flow Per Share	0.81	0.62	0.69	0.76	0.36
Dividend Per Share	0.050	0.050	0.050	0.040	0.025
Dividend Growth	-	-	25.00%	60.00%	-
Gross Margin	91.08%	91.23%	90.40%	85.92%	91.36%
Operating Margin	48.16%	55.08%	56.34%	54.09%	59.12%
Profit Margin	38.07%	40.41%	39.08%	31.77%	51.18%
Free Cash Flow Margin	42.94%	35.70%	45.82%	60.01%	38.10%
EBITDA	46.54	49.32	44.52	35.97	29.07
EBITDA Margin	48.98%	55.93%	56.85%	54.74%	60.16%
D&A For EBITDA	0.79	0.75	0.4	0.43	0.5
EBIT	45.76	48.57	44.13	35.55	28.57
EBIT Margin	48.16%	55.08%	56.34%	54.09%	59.12%
Effective Tax Rate	29.83%	29.68%	32.85%	39.17%	3.83%
Revenue as Reported	105.3	95.31	82.99	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.